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Association of Tenofovir Use With Risk of Incident Heart Failure in
HIV-Infected Patients
Ruijun Chen, MD; Rebecca Scherzer, PhD; Priscilla Y. Hsue, MD; Vasantha Jotwani, MD; Michelle M. Estrella, MD, MHS;
Michael A. Horberg, MD; Carl Grunfeld, MD, PhD; Michael G. Shlipak, MD, MPH
Background-—The antiretroviral medication, tenofovir disoproxil fumarate (TDF), is used by most human immunodeficiency virus–
infected persons in the United States despite higher risks of chronic kidney disease. Although chronic kidney disease is a strong
risk factor for heart failure (HF), the association of TDF with incident HF is unclear.
Methods and Results-—We identified 21 435 human immunodeficiency virus–infected patients in the United States Veterans
Health Administration actively using antiretrovirals between 2002 and 2011. We excluded patients with a prior diagnosis of HF.
TDF was analyzed categorically (current, past, or never use) and continuously (per year of use). Proportional hazards regression and
fully adjusted marginal structural models were used to determine the association of TDF exposure with risk of incident HF after
adjustment for demographic, human immunodeficiency virus–related, and cardiovascular risk factors. During follow-up, 438
incident HF events occurred. Unadjusted 5-year event rates for current, past, and never users of TDF were 0.9 (95%CI 0.7-1.1), 1.7
(1.4-2.2), and 4.5 (3.9-5.0), respectively. In fully adjusted analyses, HF risk was markedly lower in current TDF users (HR=0.68; 95%
CI 0.53-0.86) compared with never users. Among current TDF users, each additional year of TDF exposure was associated with a
21% lower risk of incident HF (95%CI: 0.68-0.92). When limited to antiretroviral-naive patients, HF risk remained lower in current
TDF users (HR=0.53; 95%CI 0.36-0.78) compared to never users.
Conclusions-—Among a large national cohort of human immunodeficiency virus–infected patients, TDF use was strongly
associated with lower risk of incident HF. These findings warrant confirmation in other populations, both with TDF and the recently
approved tenofovir alafenamide fumarate. ( J Am Heart Assoc. 2017;6: e005387. DOI: 10.1161/JAHA.116.005387.)
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M odern antiretroviral (ARV) therapy has revolutionizedmedical care for patients with HIV, improving life
expectancy and transitioning HIV from the realm of terminal
illness to that of chronic disease.1,2 Concomitantly, the
conditions with the highest morbidity and mortality risk
affecting HIV-infected patients have shifted from conse-
quences of severe immunodeficiency to conditions more
typically associated with aging. Cardiovascular disease
(CVD) and heart failure (HF) have become leading causes
of death among HIV-infected patients3,4 and are projected
to dramatically increase in prevalence in this population
within the next 15 years.5,6 Notably, echocardiography
reveals that contemporary HIV cohorts have high rates of
diastolic dysfunction,7,8 and HF with preserved ejection
fraction will likely increase in prevalence as in the non-HIV
population, where it already accounts for 50% of HF
cases.9
HIV infection has long been associated with HF via
suspected etiologies related directly to viral infection, such
as HIV myocarditis, increased cytokine production, and
chronic inflammation.10,11 However, a wider spectrum of HF
etiologies must be considered in the modern ARV era,
including both typical risk factors for HF and those specific to
the HIV-infected population. There is evidence of renal and
cardiac toxicity from certain ARVs used to treat HIV.12,13
Although this is not universally found, limited past studies
have shown that nucleoside reverse transcriptase inhibitors,
particularly zidovudine, may be associated with systolic
dysfunction, cardiomyopathies, and an increased risk of
myocardial infarction, and others have proposed an increased
From the Department of Medicine, San Francisco VA Medical Center and
University of California, San Francisco, CA (R.C., R.S., V.J., M.M.E., C.G.,
M.G.S.); Kidney Health Research Collaborative, University of California San
Francisco, San Francisco, CA (R.S., V.J., M.M.E., C.G., M.G.S.); Division of
Cardiology, San Francisco General Hospital, San Francisco, CA (P.Y.H.);
Mid-Atlantic Permanente Research Institute, Rockville, MD (M.A.H.).
Correspondence to: Michael G. Shlipak, MD, MPH, San Francisco Veterans
Affairs Medical Center, Box 111A1, 4150 Clement Street, San Francisco, CA
94121. E-mail: michael.shlipak@ucsf.edu
Received December 24, 2016; accepted February 21, 2017.
ª 2017 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial License, which permits use, distribu-
tion and reproduction in any medium, provided the original work is properly
cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.116.005387 Journal of the American Heart Association 1
ORIGINAL RESEARCH
risk of HF or myocardial infarction with protease inhibitors
and abacavir.14-17
To date, little is known about the cardiac effects of 1 of the
most widely used ARVs, tenofovir disoproxil fumarate (TDF),
which is frequently recommended as a first-line agent and
incorporated in multidrug formulations.18 TDF has been
consistently associated with higher risk of chronic kidney
disease, which is 1 of the strongest independent risk factors
for HF in both the general population and HIV-infected
persons.19,20 Therefore, TDF might be hypothesized to
increase patients’ risk for HF. In fact, a study evaluating the
early period of TDF use, through 2007, among Department of
Veterans Affairs (VA) patients found TDF to be associated with
a nonsignificantly increased risk of HF, but findings were
inconclusive due to the limited number of events and the
short time of exposure.14 To our knowledge, no other study
has evaluated whether TDF use impacts the risk of HF.
Accordingly, we sought to determine the association of TDF
with the incidence of HF in a larger cohort of HIV-infected
veterans with a greater prevalence of TDF use and longer-term
exposure.
Methods
Data Source
We conducted a retrospective cohort study using the HIV
Clinical Case Registry, a registry from the US VA that was
developed to monitor healthcare utilization for HIV-infected
US veterans. The registry included all HIV-infected veterans
receiving care in the VA nationally and extracted demo-
graphic, clinical, laboratory, pharmacy, healthcare utilization,
and death information from the VA electronic medical record
to a centralized database. The HIV Clinical Case Registry was
linked to the VA National Patient Care Database, the VA
Beneficiary Identification and Records Locator Subsystem
Death File, and Medicare claims to augment demographic,
comorbidity, and vital status data and to capture clinical
events outside of the VA system.
Study Population
We included all HIV-infected persons actively receiving clinical
care from the VA who initiated or received ARV therapy
between 2002 and 2011. Because FDA approval of TDF did
not occur until October 2001, we defined the baseline for
each patient as January 1, 2002 or the date of starting ARV
therapy (whichever was later). Persons diagnosed with HF
before 2002 were excluded from the analysis. In order to
identify patients actively receiving treatment at the VA, we
also excluded patients who did not have at least 1 of each of
the following criteria: HIV viral load, CD4 cell count, outpatient
visit, and assessment of kidney function. Participants were
followed until January 1, 2011, yielding a maximum follow-up
period of 9 years.
Outcomes
Our primary outcome was incident HF, defined as a new
hospitalization discharge diagnosis or ambulatory diagnosis of
HF over the study period, as determined by ICD-9 codes.
Discharge diagnoses and procedural codes entered into VA
and Medicare databases were based on validated algorithms
defined previously.19,21 For discharge diagnoses, we required
that HF be listed as the primary, secondary, or tertiary
diagnosis for the hospitalization.
Primary Predictors
Our primary predictor was exposure to TDF during the study
period, analyzed both categorically and continuously (per year
of use). We categorized patients primarily as: (1) current TDF
users (patients whose last ARV regimen during study follow-
up included TDF); (2) past TDF users (patients who discon-
tinued TDF during follow-up); and (3) never TDF users. As an
alternative categorization, we also grouped patients as being:
(1) initial TDF users (included in their initial ARV regimen); (2)
later TDF users (initiated TDF after at least 1 prior ARV
regimen); and (3) never TDF users. When evaluating duration
of TDF use, we distinguished “current duration”—length of
use among current TDF users—from “total duration,” which
included all cumulative TDF exposure.
Covariates
For adjustment variables, we included demographic and
clinical covariates, measured at each patient’s baseline, as
defined above: age, sex, race (black, white, other), diagnosis
of diabetes mellitus, diagnosis of hypertension, lipid profile,
history of CVD (coronary artery disease, stroke, transient
ischemic attack, peripheral artery disease), smoking, alco-
holism, illicit drug use, hepatitis C virus infection, hepatitis B
virus infection, BMI, proteinuria, estimated glomerular filtra-
tion rate as calculated by the Chronic Kidney Disease
Epidemiology Collaboration equation,22 serum albumin, CD4
count, nadir CD4 count within VA records, HIV RNA level, use
of highly active antiretroviral therapy, history of AIDS, duration
of HIV, and number of antihypertensive medications. We used
previously validated algorithms to define the following condi-
tions: diabetes, hypertension, hepatitis B and C virus
coinfection, AIDS, illicit drug use, and smoking.14,19,21,23,24
We adjusted for CD4 count, HIV RNA level, estimated
glomerular filtration rate, and proteinuria as time-updated
covariates in additional models.
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Statistical Analysis
We compared baseline demographic and clinical characteris-
tics across categories of TDF exposure (current/past/never
and initial/later/never) using chi-squared tests for categorical
variables and Kruskal-Wallis tests for continuous variables. We
then determined the unadjusted rates of incident HF across
categories of TDF exposure using the Fine-Gray method to
account for the competing risk of death and plotted the
cumulative incidence over time.25 The Fine-Gray competing
risk analysis is designed to account for potential bias due to
informative censoring from the competing risk of death before
onset of HF. We used Cox proportional hazards regression
models to evaluate the associations of the TDF use with
incident HF, again accounting for the competing risk of death.
We modeled TDF associations using 2 separate Cox models:
(1) the demographic model, which only adjusted for age, sex,
and race; and (2) the multivariable Cox model, which
additionally adjusted for traditional and HIV-related factors,
as listed in the covariates section above, as well as time-
dependent covariates (CD4, VL, estimated glomerular filtra-
tion rate, and proteinuria).
Because time-dependent covariates may both confound
and mediate the effects of ARV treatment in a manner that
cannot be addressed by conventional methods of analysis, we
also used marginal structural models (MSM), including all
baseline variables from the multivariable Cox model, to
reestimate the associations of TDF exposure with risk of
incident HF.26-28 We utilized MSMs to minimize drug-
channeling bias, as the decision to prescribe a specific ARV
may be influenced by unmeasured confounders. We gener-
ated inverse probability of treatment weights for each patient
by modeling TDF exposure as a function of demographic and
clinical characteristics, selected from the candidate covari-
ates listed above. We used separate multinomial logistic
regression models29 to calculate inverse probability of
treatment weights for categories of use (current, past, or
never; initial, later, or never) and linear regression models30 to
calculate weights for duration of exposure (total and current).
These weights were then applied to subsequent models
evaluating the associations of TDF with HF.31
Sensitivity Analyses
We performed multiple sensitivity analyses in order to
determine whether confounding was present and whether
the effects of TDF differed by subgroup. We first limited our
cohort to only ARV-naive patients, defined as patients with no
exposure to ARVs before the study period, to minimize the
bias and confounding that may exist from previous ARV
exposure in our cohort. We also performed additional
sensitivity analyses to adjust for calendar year and for era
of initiation, defined as early era (ARV initiation before 2003)
or late era (ARV initiation in 2003 or later), to determine
whether effects may differ across time.
Because numerous risk factors exist for HF that may be
influenced by TDF use, we then stratified our cohort into
multiple subgroups based on patient characteristics and risk
factors that may represent potential confounders. We calcu-
lated the hazard ratio (HR) per year of current TDF exposure
for each subgroup using the marginal structural model. We
created a forest plot to help illustrate whether the overall
associations from the primary analysis were driven by any
particular interaction or subgroup. We stratified our cohort
based on the following factors: age, race, proteinuria, chronic
kidney disease, CD4 count, viral load, diabetes, hypertension,
history of cardiovascular disease, cholesterol, smoking status,
illicit drug use, hepatitis C infection, BMI, albumin, alcoholism,
and era of initiation.
Given the history of adverse cardiac effects with abacavir
use, we modeled TDF and abacavir in various combinations to
determine whether abacavir use, or lack thereof, may explain
any associations between TDF and HF. Finally, because
myocardial infarction and ischemia are important etiologies of
HF, we adjusted for interim myocardial infarction in an
additional sensitivity analysis.
All analyses were conducted using SAS version 9.4 (SAS
Institute Inc, Cary, NC). This study was approved by the
Committee on Human Research at the San Francisco VA
Medical Center and University of California, San Francisco,
and the requirement for informed consent was waived.
Results
Patient Characteristics
We identified 21 435 HIV-infected patients who initiated ARVs
in the Veterans Health Administration between 2002 and
2011. At baseline, median age was 49 years (interquartile
range [IQR] 42-55), and 97% of patients were male. Median
duration on TDF was 2.2 years (IQR 0.8-4.0), and mean
duration was 2.6 years (SD 2.1). There were 11 881 patients
whose ARV regimens at the conclusion of the study period
included TDF (current TDF users), 3979 patients whose ARV
regimens included TDF in the past (past TDF users), and 5575
patients who never used TDF (never TDF users). At baseline,
age and sex appeared similar across these 3 groups (Table 1).
Relative to past and never TDF users, current TDF users had a
slightly lower proportion of diabetes mellitus, hypertension,
preexisting CVD, history of alcoholism, history of illicit drug
use, and hepatitis C infection at baseline. Current users also
had a higher median duration on TDF and slightly higher
estimated glomerular filtration rate. Former users of TDF had
the lowest CD4 counts and the highest prevalence of
DOI: 10.1161/JAHA.116.005387 Journal of the American Heart Association 3
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detectable HIV RNA at baseline and at end of the study
(Table 1). When comparing characteristics of initial, later, and
never TDF users, we found that initial TDF users had a slightly
lower prevalence of comorbidities compared with later or
never TDF users; however, they also had lower CD4 counts
and a higher viral load at treatment initiation (Table 2).
Risk of Incident Heart Failure
Over a median of 5.4 years of follow-up, there were 438
incident HF events. The unadjusted incidence of HFwas highest
among never users of TDF, followed by past and current users of
TDF, along with later and initial TDF users (Figure 1).
Unadjusted 5-year incidences for current, past, and never
users of TDF were 0.9% (110 events; 95%CI 0.7-1.1), 1.7% (79
events; 95%CI 1.4-2.2), and 4.5% (249 events; 95%CI 3.9-5.0),
respectively. Unadjusted 5-year incidences of HF were similar
for initial and later TDF users, although both rates were
substantially lower than the incidence among never users of
TDF: 1.1% (45 events; 95%CI 0.8-1.5), 1.1% (144 events; 95%CI
0.9-1.3), and 4.5% (249 events; 95%CI 3.9-5.0), respectively.
Greater cumulative TDF exposure among ever TDF users
was associated with a significantly decreased adjusted HF risk
in both the demographically adjusted and multivariable
models (Table 3). However, additional adjustment with the
MSM widened the confidence interval, and the association
lost statistical significance. In contrast, current TDF exposure
was more strongly and significantly associated with lower HF
risk in all models; each year of current TDF use was
associated with an 20% lower risk of HF.
In our categorical analyses comparing current, former, and
never TDF users, we found that current users of TDF had
Table 1. Baseline Patient Characteristics Stratified by Current/Past/Never TDF Use
Current TDF Use Past TDF Use Never TDF
N=11 881 N=3979 N=5575
Age, y 48 (41, 54) 48 (42, 55) 50 (44, 56)
Female 331 (3%) 116 (3%) 121 (2%)
Black 5976 (50%) 2253 (57%) 3081 (55%)
Duration of TDF exposure, y 2.5 (1.1-4.3) 1.5 (0.5-2.7) 0
Diabetic 804 (7%) 391 (10%) 568 (10%)
Hypertension 2928 (25%) 1246 (31%) 1674 (30%)
Total cholesterol, mg/dL 174 (148, 204) 173 (144, 202) 178 (149, 210)
Low-density lipoprotein cholesterol, mg/dL 101 (79, 127) 97 (75, 123) 101 (78, 129)
High-density lipoprotein cholesterol, mg/dL 38 (30, 48) 38 (30, 48) 40 (32, 51)
Triglycerides, mg/dL 139 (93, 217) 141 (98, 223) 147 (98, 230)
Cardiovascular disease 598 (5%) 241 (6%) 420 (8%)
History of smoking 3231 (27%) 1096 (28%) 1598 (29%)
History of illicit drug use 3554 (30%) 1376 (35%) 1890 (34%)
History of alcoholism 2179 (18%) 945 (24%) 1256 (23%)
BMI, kg/m2 25 (23, 28) 24 (22, 28) 25 (22, 28)
Serum albumin, g/dL 4.0 (3.6, 4.3) 3.9 (3.5, 4.2) 3.9 (3.5, 4.2)
Proteinuria (>30 mg/dL) 2275 (19%) 977 (25%) 1225 (22%)
eGFR by CKD-EPI 97 (84, 109) 95 (80, 108) 93 (76, 107)
Highly active antiretroviral therapy 10 399 (88%) 3202 (80%) 4378 (79%)
CD4 count, cells/mm3 (baseline) 336 (189, 526) 291 (138, 479) 379 (206, 615)
CD4 count, cells/mm3 (end) 455 (281, 657) 328 (144, 539) 457 (250, 687)
HIV RNA >1000, copies/mL (baseline) 6735 (58%) 2437 (62%) 2397 (45%)
HIV RNA >1000, copies/mL (end) 1696 (15%) 1401 (36%) 1516 (28%)
Chronic hepatitis C 3048 (26%) 1300 (33%) 1780 (32%)
Chronic hepatitis B 1170 (10%) 477 (12%) 567 (10%)
P<0.05 for all characteristics across all 3 groups except for smoking (P=0.13). The P-value for TDF duration is <0.0001. Continuous variables reported as median (interquartile range; IQR).
Proteinuria defined by urinalysis protein 30 mg/dL or greater. Baseline defined for each patient as January 1, 2002 or the date of starting ARV therapy (whichever was later). End defined
as January 1, 2011. CKD-EPI indicates Chronic Kidney Disease Epidemiology Collaboration equation; eGFR, estimated glomerular filtration rate; TDF, tenofovir disoproxil fumarate.
DOI: 10.1161/JAHA.116.005387 Journal of the American Heart Association 4
Association of Tenofovir With Heart Failure Risk Chen et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
30% to 40% lower HF risk compared to never or to past
users (Table 3). There was only minimal attenuation from the
demographic model to the multivariable and marginal struc-
tural models in the comparison of current to never users, and
the comparison of current to past users also remained
significant in the multivariable model but not in the MSM
(Table 3). Initial TDF users had a more than 50% lower HF risk
compared to never users of TDF, which also remained
consistent across all models (Table 3). There were no
statistically significant differences in adjusted HF risk
between past and never TDF users or between later and
never TDF users.
Table 2. Additional Patient Characteristics Stratified by Initial/Later/Never TDF Use
Initial Regimen Included TDF Later TDF (2°/3° Regimen) Never TDF
N=7090 N=8770 N=5575
Age, y (baseline) 49 (42, 56) 47 (41, 53) 50 (44, 56)
Female 221 (3%) 226 (3%) 121 (2%)
Black 3697 (52%) 4532 (52%) 3081 (55%)
Duration of TDF exposure, years 1.7 (0.7-3.3) 2.7 (1.1-4.5) 0
Diabetic (baseline) 470 (7%) 725 (8%) 568 (10%)
Hypertension (baseline) 1232 (17%) 2942 (34%) 1674 (30%)
Total cholesterol, mg/dL (baseline) 166 (141, 193) 180 (152, 212) 178 (149, 210)
Low-density lipoprotein cholesterol, mg/dL (baseline) 98 (77, 120) 102 (80, 130) 101 (78, 129)
High-density lipoprotein cholesterol, mg/dL (baseline) 36 (29, 46) 39 (32, 50) 40 (32, 51)
Triglycerides, mg/dL (baseline) 128 (88, 192) 151 (101, 240) 147 (98, 230)
Cardiovascular disease (baseline) 335 (5%) 504 (6%) 420 (8%)
History of smoking (baseline) 1910 (27%) 2417 (28%) 1598 (29%)
History of illicit drug use (baseline) 1969 (28%) 2961 (34%) 1890 (34%)
History of alcoholism (baseline) 1088 (15%) 2036 (23%) 1256 (23%)
BMI, kg/m2 (baseline) 25 (22, 28) 25 (23, 28) 25 (22, 28)
Serum albumin, g/dL (baseline) 3.9 (3.5, 4.3) 4.0 (3.7, 4.3) 3.9 (3.5, 4.2)
Proteinuria (>30 mg/dL; baseline) 1952 (28%) 1300 (15%) 1225 (22%)
eGFR by CKD-EPI (baseline) 95 (81, 108) 97 (84, 110) 93 (76, 107)
eGFR by CKD-EPI (end) 91 (76, 106) 89 (72, 103) 90 (69, 106)
Highly active antiretroviral therapy (baseline) 7011 (99%) 6590 (75%) 4378 (79%)
Highly active antiretroviral therapy (ever use at end) 7074 (99.8%) 8768 (99.9%) 5422 (97%)
CD4 count, cells/mm3 (baseline) 297 (157, 451) 352 (190, 564) 379 (206, 615)
CD4 count, cells/mm3 (end) 432 (257, 612) 423 (234, 648) 457 (250, 687)
Nadir CD4 count, cells/mm3 (baseline) 278 (141, 417) 277 (121, 463) 298 (140, 513)
Nadir CD4 count, cells/mm3 (end) 240 (109, 377) 186 (59, 333) 240 (90, 408)
History of AIDS (baseline) 2857 (40%) 4219 (48%) 2503 (45%)
History of AIDS (end) 4719 (67%) 7074 (81%) 3862 (69%)
Duration of HIV (baseline) 0.4 (0.0, 3.6) 3.2 (0.6, 5.3) 2.2 (0.2, 5.0)
Duration of HIV (end) 4.2 (1.8, 7.2) 11.0 (8.0, 13.6) 8.1 (4.2, 12.0)
HIV RNA >1000, copies/mL (baseline) 4668 (68%) 4504 (52%) 2397 (45%)
HIV RNA >1000, copies/mL (end) 1266 (18%) 1831 (21%) 1516 (28%)
Chronic hepatitis C (baseline) 1666 (23%) 2682 (31%) 1780 (32%)
Chronic hepatitis B (baseline) 594 (8%) 1053 (12%) 567 (10%)
P<0.05 for all variables except BMI and smoking (baseline). Continuous variables are reported as median (interquartile range; IQR). Proteinuria is defined by urinalysis protein 30 mg/dL or
greater. Baseline is defined for each patient as January 1, 2002 or the date of starting ARV therapy (whichever was later). End is defined as January 1, 2011. AIDS indicates acquired
immune deficiency syndrome; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration equation; eGFR, estimated glomerular filtration rate; TDF, tenofovir disoproxil fumarate.
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Based on HRs from the MSM, we found that current TDF
use was associated with a number needed to treat of 71 over
5 years (absolute risk reduction 1.41%). This estimate
decreased to a number needed to treat of 41 (absolute risk
reduction 2.44%) for those who used TDF as part of their
initial regimen (Table 4).
Sensitivity Analyses
In an effort to further minimize confounding, we performed
several sensitivity analyses. We first repeated our analyses
after restricting the patient population to those who were ARV
naive at baseline (Table 5). The associations of continuous
measures of total and current TDF exposure with HF risk had
similar point estimates as in the overall analysis, but the wider
confidence intervals led the findings to be nonsignificant by
statistical criteria. However, associations of current versus
never TDF users and of initial versus never TDF users were
both strong and statistically significant in the ARV-naive group
throughout all stages of statistical adjustment, consistent
with our findings in the overall analysis (Table 5).
Additional sensitivity analyses were performed to deter-
mine whether there was a time effect, either by calendar year
or by era of initiation, that may explain our results.
Adjustment for calendar year of ARV initiation did not impact
our results. Specifically, the association of current TDF
duration (per year of exposure) with HF risk was HR 0.81
(95%CI 0.69-0.94, P=0.0049) after adjustment for calendar
year. When stratified by era of ARV initiation, the protective
effect of current TDF duration appears to be somewhat
stronger in the early era (HR 0.76 [95%CI 0.63-0.91],
P=0.0024), as compared to the late era (HR 0.89 [95%CI
0.68-1.16], P=0.39). However, there was no significant
interaction between era of ARV initiation and duration (test
for interaction, P=0.34).
After stratifying the cohort by subgroups based on patient
characteristics and risk factors which may be potential
confounders, we found that the HR for TDF had similar,
protective associations with incident HF across all subgroups
of patients (Figure 2). Tests for TDF-by-subgroup interaction
were statistically nonsignificant (all P>0.13). This suggests
that no single group was responsible for driving the overall
association of TDF use with lower HF risk seen in the primary
analysis. In our analysis of the effects of TDF and abacavir, we
found that when modeled simultaneously, current TDF
duration was associated with a lower risk of HF (HR 0.82
[95% CI 0.71-0.94], P=0.0059), whereas current abacavir
duration was not significantly associated with HF risk (HR
0.97 [95% CI 0.85-1.10], P=0.64). When modeled in various
combinations and compared with patients using neither, we
found that the point estimates were similar for TDF use with
(HR 0.76; 95% CI 0.41-1.40) or without (HR 0.75; 95% CI 0.59-
0.96) abacavir, relative to users of neither agent. Use of
abacavir alone was not significantly associated with incident
HF (HR 1.15; 95% CI 0.87-1.52), but the point estimate was in
the opposite direction from TDF. Finally, when adjusted for
interim myocardial infarction, we found that the association of
each year of current TDF use remained associated strongly
with lower risk of HF (HR 0.83 [95% CI 0.72-0.96] P=0.014).
Discussion
We embarked on this study with the hypothesis that the use
of TDF would be associated with a higher risk of incident HF
due to this drug’s known link to worsening kidney function
and previous preliminary data.14,19,20 However, in this large
national registry of HIV-infected US veterans, we found that
TDF exposure was actually associated with a significantly
Figure 1. Cumulative incidence of heart failure by category of
TDF exposure. Unadjusted incidence of heart failure was highest
among never users of TDF, followed by past and current users of
TDF. Similarly never TDF users also had the highest incidence of
heart failure when compared with initial and later TDF users. CHF
indicates heart failure, TDF, tenofovir disoproxil fumarate.
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lower risk of HF. Across multiple statistical models, this
observed protective association of TDF persisted in both
continuous and categorical measures of TDF exposure.
Compared with never users of TDF, current users of TDF
and patients whose initial regimen included TDF had reduc-
tions in HF risk ranging from 30% to 50%. To our knowledge,
this is the first large national cohort study to identify a
significant association between TDF use and HF risk in HIV-
infected patients. These novel results suggest that TDF may
offer cardioprotective benefits, but our findings require
confirmation in additional settings before they can be
considered to definitively represent a causal relationship.
Previously, there has been limited literature regarding the
association of ARVs with CVD, including conflicting data
regarding the increased risk of CVD with specific classes of
ARVs, most of which focused on atherosclerosis or coronary
artery disease.16,32-36 However, despite well-known associa-
tions of HIV infection with HF and cardiomyopathies, few
studies have evaluated ARVs and HF.10,11,37 In case reports
and mouse models, there was early evidence that the
nucleoside reverse transcriptase inhibitor zidovudine
might worsen cardiomyopathy through mitochondrial destruc-
tion.38-40 Subsequent studies found that certain protease
inhibitors may also be associated with increased HF inci-
dence.17,41 To our knowledge, no large study has previously
concluded that any individual ARV or class of ARVs has a
protective effect against the development of HF.8,10,11
Initially, we expected that TDF exposure would be asso-
ciated with an increased risk for HF. This seemed biologically
plausible due to TDF’s adverse effects on kidney disease risk
Table 3. Association of TDF Exposure With Risk of Incident Heart Failure for All Patients With HIV (N=21 435), Accounting for
Competing Risk of Death
Parameter
Demographic-Adjusted Cox Model* Multivariable Adjusted Cox Model† Marginal Structural Model‡
Hazard Ratio (95%CI) Hazard Ratio (95%CI) Hazard Ratio (95%CI)
Continuous TDF exposure (per year)
Total TDF duration 0.88 (0.82-0.96) P=0.003 0.91 (0.84-0.99) P=0.037 0.92 (0.83-1.02) P=0.11
Current TDF duration 0.73 (0.62-0.85) P<0.001 0.78 (0.67-0.91) P=0.001 0.79 (0.68-0.92) P=0.003
Categories of TDF use
Current vs never TDF use 0.60 (0.48-0.75) P<0.001 0.66 (0.52-0.84) P<0.001 0.68 (0.53-0.86) P=0.002
Past vs never TDF use 1.06 (0.82-1.37) P=0.67 0.98 (0.76-1.27) P=0.89 0.87 (0.66-1.15) P=0.33
Current vs past TDF use 0.57 (0.42-0.76) P<0.001 0.67 (0.50-0.90) P=0.008 0.77 (0.57-1.06) P=0.11
Categories of TDF use
Initial regimen included TDF vs never TDF use 0.42 (0.30-0.58) P<0.001 0.47 (0.33-0.65) P<0.001 0.44 (0.30-0.64) P<0.001
Later TDF (2°/3° regimen) vs never TDF use 0.77 (0.62-0.95) P=0.017 0.89 (0.71-1.11) P=0.30 0.96 (0.76-1.21) P=0.73
TDF indicates tenofovir disoproxil fumarate.
*Demographic adjusted Cox model includes TDF exposure, age, sex, and race.
†Multivariable adjusted Cox model includes exposure to tenofovir plus age, sex, race/ethnicity, traditional risk factors, and HIV-related risk factors, as listed in covariates section.
‡Marginal structural model includes all baseline variables from multivariable Cox model.
Table 4. Summary of HF Events and Person-Years by TDF Exposure
Category Events
Person-
Years
Five-Year Cumulative
Incidence From
Fine-Gray Model
Event-Free
Rate
Hazard Ratio
From MSM NNT*
Current TDF (N=11 881) 110 61 516 0.0080 0.992 0.68 71
Past TDF (N=3979) 79 22 691 0.0125 0.988 0.87 176
Never (N=5575) 249 27 918 0.0445 0.956
Initial TDF (N=7090) 45 19 776 0.0097 0.990 0.44 41
Later TDF (N=8770) 144 64 431 0.0081 0.992 0.96 574
Never (N=5575) 249 27 918 0.0445 0.956
NNT(t) ¼ 1
SB tð Þð ÞHRSB tð Þ
, where SB(t) denotes the survival probability in the never TDF group at t=5 years, and HR indicates the hazard ratio for each TDF-use category relative to the never
TDF group. HF indicates heart failure; MSM, marginal structural model; TDF, tenofovir disoproxil fumarate.
*Number needed to treat (NNT) indicates that if 71 patients were treated with TDF over 5 years, 1 case of HF would be prevented that would have otherwise occurred.
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and the known associations of reduced kidney function with
elevated HF risk. In addition, a previous study in this
population found early TDF users to have higher rates of HF
in unadjusted analyses but was limited by a short mean time
on TDF of 1.3 years.14,19,20 Therefore, our finding that TDF
appears to be associated with a decreased risk of HF was
unexpected. Nonetheless, there are a number of candidate
mechanisms for a potential protective effect. The first is
potentially superior viral control of HIV with treatment
combinations that include TDF, which may subsequently
reduce inflammation and levels of cytokines that cause
cardiac injury. Supporting this hypothesis, 1 study has found
that higher HIV viral loads were associated with higher HF
risk.37
Another intriguing possibility to explain this beneficial
effect of TDF is through its known phosphaturic effects on the
kidney. Although phosphate losses caused by TDF have been
linked with bone disease, they also have the salient effect of
lowering levels of fibroblast growth factor 23, a phosphaturic
hormone that acts on the bones and kidney. Fibroblast growth
factor 23 causes pathological hypertrophy of cardiomyocytes
in mechanistic studies and is strongly and independently
associated with left ventricular hypertrophy and HF risk in
epidemiological studies.42-47 Thus, this potentially adverse
effect of TDF causing phosphorus wasting from the kidney
may actually result in lower HF risk due to the favorable
effects of reduced levels of fibroblast growth factor 23.
A third possible mechanism is via TDF’s potential lipid-
lowering effects. Multiple studies have noted a more favorable
lipid profile in TDF users, and a recent trial showed significant
decreases in total and low-density lipoprotein cholesterol.48
Whereas other ARV regimens have a side effect of dyslipi-
demia, TDF could create a potentially beneficial reduction in
atherosclerosis and subsequent coronary artery disease.
Indeed, TDF use has been associated with decreased carotid
intima-media thickness.49 These favorable vascular effects
could reduce the incidence of ischemic HF. However, we
observed only mild changes in lipid profile across the various
categories of TDF use from baseline to the end of our study
period, and the protective effect of TDF remained similar after
adjustment for interim myocardial infarction. Further investi-
gation to uncover the mechanisms that may potentiate TDF’s
protective effect is still needed.
Several factors should be considered in interpreting our
study. First, the fact that 40% of our patients had been
exposed to ARVs before the start of our study period may
introduce important bias and confounding, particularly if their
HIV was either well controlled or difficult to control on their
preexisting regimens before the introduction of TDF. However,
a sensitivity analysis including only ARV-naive patients
actually showed similar protective associations for TDF.
Second, we were unable to distinguish between systolic and
diastolic HF, and we did not have echocardiographic data to
help determine the mechanisms of these putative protective
effects. We were also unable to determine whether the use or
avoidance of nephrotoxic medications such as nonsteroidal
anti-inflammatory drugs may have influenced our findings, as
we could not reliably assess the use of these over-the-counter
medications. Finally, we cannot rule out unmeasured con-
founding as the explanation for these associations. However,
our findings persisted after MSM adjustment for drug
channeling bias and after numerous sensitivity and subgroup
Table 5. Association of TDF Exposure With Risk of Incident Heart Failure Among ARV-Naive Only Patients With HIV (N=12 925),
Accounting for Competing Risk of Death
Parameter
Demographic-Adjusted Cox Model* Multivariable Adjusted Cox Model† Marginal Structural Model‡
Hazard Ratio (95%CI) Hazard Ratio (95%CI) Hazard Ratio (95%CI)
Continuous TDF exposure
Total TDF duration (per year) 0.79 (0.67-0.93) P<0.01 0.86 (0.73-1.00) P=0.06 0.81 (0.65-1.01) P=0.06
Current TDF duration (per year) 0.73 (0.57-0.94) P=0.02 0.82 (0.64-1.04) P=0.11 0.87 (0.68-1.12) P=0.29
Categories of TDF use
Current vs never TDF use 0.47 (0.33-0.67) P<0.01 0.56 (0.39-0.81) P<0.01 0.53 (0.36-0.78) P<0.01
Past vs never TDF use 0.89 (0.58-1.36) P=0.58 0.91 (0.59-1.41) P=0.67 0.81 (0.51-1.29) P=0.37
Categories of TDF use
Initial regimen included TDF vs never TDF use 0.44 (0.30-0.65) P<0.01 0.55 (0.36-0.83) P<0.01 0.52 (0.32-0.83) P<0.01
Later TDF (2°/3° regimen) vs never TDF use 0.69 (0.47-1.01) P=0.06 0.91 (0.61-1.35) P=0.65 0.94 (0.62-1.42) P=0.77
ARV indicates antiretroviral; TDF, tenofovir disoproxil fumarate.
*Demographic adjusted Cox model includes TDF exposure, age, sex, and race.
†Multivariable adjusted Cox model includes exposure to tenofovir plus age, sex, race/ethnicity, traditional risk factors, and HIV-related risk factors, as listed in covariates section. Also
adjusted for CVD, history of AIDS, nadir CD4, duration of HIV, and number of antihypertensive medications.
‡Marginal structural model includes all baseline variables from multivariable Cox model.
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analyses, so we believe that confounding alone is an unlikely
explanation for the effect of TDF on HF risk. Our results also
may not be generalizable to other populations, as our cohort
consisted predominantly of male US veterans who are actively
treated in a comprehensive integrated healthcare system.
In this large national sample of predominantly male
patients with HIV, we observed that TDF use was strongly
associated with a lower risk of incident HF. This association
was most prominent for patients who were currently on TDF
at the end of the study period or those who started on
Figure 2. Association of current TDF exposure with incident HF stratified across
subgroups of patient characteristics and risk factors. Point estimates of HRs for
incident HF across all subgroups showed a similarly protective effect of TDF,
suggesting that no single group or factor was driving the overall association of TDF use
with lower risk of HF. Tests for TDF-by-subgroup interaction were statistically
nonsignificant (all P>0.13). Patient characteristics and risk factors were obtained from
covariates in marginal structural model. Early era defined as before 2003; late era
defined as after 2003. CKD indicates chronic kidney disease; CVD, cardiovascular
disease; DM, diabetes mellitus; HCV, hepatitis C; HDL, high-density lipoprotein; HF,
heart failure; HR, hazard ratio; HTN, hypertension; LDL, low-density lipoprotein; TDF,
tenofovir disoproxil fumarate; TG, triglycerides; VL, viral load.
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TDF as part of their initial ARV regimen. The association of
TDF with HF risk warrants additional study in other clinical
settings and populations, including users of preexposure
prophylaxis, and potential mechanisms should be evaluated.
If this positive association of TDF on HF risk is confirmed
across populations, then it would also need to be evaluated
for the newer formulation of tenofovir, tenofovir alafenamide
fumarate, which has much lower circulating concentrations
than TDF.
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